ProAir HFA Sales Data
| Rank 41 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows ProAir HFA U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 41 ( 7) |
$306,461 | 10.87% | 7,730 | 9.86% |
| Q3 2013 | 48 ( 1) |
$276,426 | 0.09% | 7,036 | -0.87% |
| Q2 2013 | 47 (9) |
$276,177 | 5.28% | 7,098 | 4.92% |
| Q1 2013 | 56 (11) |
$262,338 | -7.84% | 6,765 | -11.64% |
| Q4 2012 | 45 (7) |
$284,649 | 6.33% | 7,656 | 5.06% |
| Q3 2012 | 52 (12) |
$267,692 | 12.06% | 7,287 | 8.31% |
| Q2 2012 | 64 (11) |
$238,874 | -16.08% | 6,728 | -15.04% |
| Q1 2012 | 53 (16) |
$284,647 | 18.08% | 7,919 | 13.65% |
| Q4 2011 | 69 (3) |
$241,059 | 1.93% | 6,968 | -5.70% |
| Q3 2011 | 66 (8) |
$236,487 | 9.84% | 7,389 | 4.51% |
| Q2 2011 | 74 (1) |
$215,302 | -6.71% | 7,070 | -2.92% |
| Q1 2011 | 73 | $230,795 | n/a | 7,283 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
